AnGes Inc. is at the forefront of gene medicine, focusing on innovative therapies that leverage nucleic acid medicine and genomic drug discovery. The company has developed several key products, including the HGF gene therapy, which utilizes plasmid DNA to treat chronic arterial occlusive disease. This groundbreaking therapy, which was the first of its kind to be commercialized globally, aims to promote angiogenesis—the formation of new blood vessels—thereby addressing ischemic conditions where blood flow is compromised. Additionally, AnGes is advancing the NF-κB decoy oligonucleotide, designed to inhibit excessive inflammatory responses, and is actively developing DNA vaccines targeting various diseases, including hypertension and COVID-19.

The company’s research extends to the development of a therapeutic vaccine for cervical intraepithelial neoplasia (CIN), which aims to eliminate precancerous cervical tissue through a novel mechanism that activates cell-mediated immunity. AnGes has also partnered with other organizations to enhance its research capabilities and expand its product pipeline, which includes ongoing projects for chronic hepatitis B and other conditions. By integrating advanced gene therapy techniques and innovative vaccine formulations, AnGes Inc. is positioning itself as a leader in the evolving field of gene medicine, with a commitment to addressing unmet medical needs through cutting-edge biopharmaceutical solutions.

Japan

AnGes was founded In December 1999, with the aim of developing hepatocyte growth factor (HGF) gene therapy drugs which can help regenerate blood vessels. Originating from the word angiogenesis meaning the formation of new blood vessels in English, our corporate name AnGes encapsulates our desire to be an angel (ange in French) offering new drugs for patients with hard-to-treat and rare diseases. Both our founder and our employees are still motivated by this desire.

AnGes Inc.

Company Details